ArticleFrontiers in immunology2026
Duodenal tuberculosis with probable biliary involvement in primary Sjögren's syndrome mimicking pancreatobiliary malignancy: a case report.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Extrapulmonary tuberculosis can imitate malignancy and systemic autoimmune disease. Concurrent duodenal tuberculosis with probable biliary involvement is exceptionally uncommon and may create a high-stakes pancreatobiliary cancer mimic. Case presentation: A 71-year-old Han Chinese woman with primary Sjögren's syndrome and type 2 diabetes, and no recent immunosuppressive therapy, presented with polyarthralgia, intermittent fever, abdominal discomfort, anorexia, constipation, and weight loss. Laboratory testing showed systemic inflammation and a cholestatic enzyme pattern, whereas bilirubin and tumor markers remained normal. Magnetic resonance cholangiopancreatography revealed diffuse bile-duct wall thickening with severe distal common bile duct stenosis, and positron emission tomography-computed tomography showed hypermetabolic duodenal thickening with multiple fluorodeoxyglucose-avid lymph nodes. The tuberculin skin test measured 15 x 12 mm at 48 and 72 hours, and interferon-gamma release assay was positive (T-N >10.00 IU/mL). Upper endoscopy demonstrated a duodenal ulcer with fistula formation, and biopsy showed ulceration, granulomatous inflammation, and one acid-fast bacillus on staining. Supraclavicular lymph-node aspiration revealed lymphocytes and multinucleated giant cells without malignant cells. Duodenal tuberculosis with nodal disease and probable, non-biopsy-proven biliary involvement was diagnosed. After discharge, she received specialist-supervised antituberculosis therapy including isoniazid 0.3 g daily, rifampicin 0.45 g daily, and levofloxacin 0.5 g daily; by January 2022, treatment had continued for more than 3 months. The initial phase structure and total treatment duration could not be reliably ascertained. Symptoms, inflammatory and cholestatic markers, endoscopic ulceration, fistula, lymph-node size, and common bile duct stenosis improved at reassessment in January 2022. Conclusion: Tuberculosis should remain in the differential diagnosis of fluorodeoxyglucose-avid duodenal and biliary lesions in patients with autoimmune disease, particularly when biochemical obstruction, tumor markers, and tissue pathology do not fit malignancy. Early endoscopic biopsy and accessible nodal sampling can prevent unnecessary surgery and unsafe escalation of immunosuppression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.